81 related articles for article (PubMed ID: 33420283)
1. CD38 expression by plasma cells in extramedullary multiple myeloma.
Notarfranchi L; Accardi F; Mancini C; Martella E; Bonomini S; Segreto R; Vescovini R; Palma ABD; Sammarelli G; Todaro G; Storti P; Burroughs-Garcia J; Iannozzi NT; Raimondi V; Lungu O; Ricci S; Craviotto L; Giuliani N
Haematologica; 2024 Apr; 109(4):1297-1300. PubMed ID: 37941401
[No Abstract] [Full Text] [Related]
2. Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells.
Kikuchi J; Hori M; Osada N; Matsuoka S; Suzuki A; Kakugawa S; Yasui H; Harada T; Tenshin H; Abe M; Nakasone H; Furukawa Y
Haematologica; 2024 Jun; ():. PubMed ID: 38867588
[TBL] [Abstract][Full Text] [Related]
3. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC; Dietrich O; Truger M; Arampatzi P; Duell J; Heidemeier A; Zhou X; Danhof S; Kraus S; Chatterjee M; Meggendorfer M; Twardziok S; Goebeler ME; Topp MS; Hudecek M; Prommersberger S; Hege K; Kaiser S; Fuhr V; Weinhold N; Rosenwald A; Erhard F; Haferlach C; Einsele H; Kortüm KM; Saliba AE; Rasche L
Nat Med; 2021 Apr; 27(4):616-619. PubMed ID: 33619368
[TBL] [Abstract][Full Text] [Related]
4. Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
Awwad MHS; Mahmoud A; Bruns H; Echchannaoui H; Kriegsmann K; Lutz R; Raab MS; Bertsch U; Munder M; Jauch A; Weisel K; Maier B; Weinhold N; Salwender HJ; Eckstein V; Hänel M; Fenk R; Dürig J; Brors B; Benner A; Müller-Tidow C; Goldschmidt H; Hundemer M
Leukemia; 2021 Sep; 35(9):2602-2615. PubMed ID: 33597728
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with difficult-to-treat multiple myeloma.
Richter J; Ramasamy K; Rasche L; Bladé J; Zweegman S; Davies F; Dimopoulos M
Future Oncol; 2021 Jun; 17(16):2089-2105. PubMed ID: 33706558
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA sequencing: one step closer to the clinic.
Sklavenitis-Pistofidis R; Getz G; Ghobrial I
Nat Med; 2021 Mar; 27(3):375-376. PubMed ID: 33664491
[No Abstract] [Full Text] [Related]
7. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A; Bilous M; Liu YC; Li X; Saillard M; Cenerenti M; Rockinger GA; Wyss T; Guillaume P; Schmidt J; Genolet R; Ercolano G; Protti MP; Reith W; Ioannidou K; de Leval L; Trapani JA; Coukos G; Harari A; Speiser DE; Mathis A; Gfeller D; Altug H; Romero P; Jandus C
Sci Adv; 2021 Feb; 7(9):. PubMed ID: 33637530
[TBL] [Abstract][Full Text] [Related]
9. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.
Zhou X; Rasche L; Kortüm KM; Danhof S; Hudecek M; Einsele H
Front Immunol; 2020; 11():620312. PubMed ID: 33424871
[TBL] [Abstract][Full Text] [Related]
10. Programmable multispecific DNA-origami-based T-cell engagers.
Wagenbauer KF; Pham N; Gottschlich A; Kick B; Kozina V; Frank C; Trninic D; Stömmer P; Grünmeier R; Carlini E; Tsiverioti CA; Kobold S; Funke JJ; Dietz H
Nat Nanotechnol; 2023 Nov; 18(11):1319-1326. PubMed ID: 37591933
[TBL] [Abstract][Full Text] [Related]
11. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Microenvironment for Treating Multiple Myeloma.
Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
[TBL] [Abstract][Full Text] [Related]
13. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond.
Strassl I; Schreder M; Steiner N; Rudzki J; Agis H; Künz T; Müser N; Willenbacher W; Petzer A; Neumeister P; Krauth MT
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572927
[TBL] [Abstract][Full Text] [Related]
14. The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies.
Einsele H; Briones J; Ciceri F; García Cadenas I; Falkenburg F; Bolaños N; Heemskerk HMM; Houot R; Hudecek M; Locatelli F; Morgan K; Morris EC; O'Dwyer M; Sierra JG; van den Brink M; van de Loosdrecht AA
Hemasphere; 2021 Oct; 5(10):e642. PubMed ID: 34522844
[No Abstract] [Full Text] [Related]
15. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.
Romano A; Storti P; Marchica V; Scandura G; Notarfranchi L; Craviotto L; Di Raimondo F; Giuliani N
Front Oncol; 2021; 11():684561. PubMed ID: 34307150
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
Geis M; Nowotny B; Bohn MD; Kouhestani D; Einsele H; Bumm T; Stuhler G
Commun Biol; 2021 Jan; 4(1):44. PubMed ID: 33420283
[TBL] [Abstract][Full Text] [Related]
17. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N; Malavasi F
Front Immunol; 2019; 10():1945. PubMed ID: 31475006
[No Abstract] [Full Text] [Related]
19. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
